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Introduction: Nuclear factor-B (NF-B) transcription factor regulates several cell signaling pathways, such as
differentiation and inflammation, which are both altered in osteoarthritis. Inhibitor B kinase (IKK)a and IKKb are
kinases involved in the activation of the NF-B transcription factor. The aim of the present study was to determine
the effects of glucosamine (GlcN), which is administered in the treatment of osteoarthritis, and of its 2-(N-Acetyl)-L-
phenylalanylamido-2-deoxy-b-D-glucose (NAPA) derivative on IKK kinases and, consequently, on NF-B activation in
human chondrocytes.
Methods: The human chondrosarcoma cell line HTB-94 and human primary chondrocytes were stimulated with
tumor necrosis factor (TNF)a after pre-treatment with GlcN or NAPA. Gene mRNA expression level was evaluated
by real-time PCR. Inhibitor B protein (IB)a phosphorylation and p65 nuclear re-localization were analyzed by
Western blotting; IKKa nuclear re-localization was also investigated by immunocytochemistry and Western blotting.
IKK kinase activity was studied by in vitro kinase assay.
Results: After TNFa stimulation, the mRNA expression level of some of the genes under NF-B control, such as
interleukin (IL)-6 and IL-8, increased, while treatment with GlcN and NAPA reverted the effect. We investigated the
possibility that GlcN and NAPA inhibit IKK kinase activity and found that NAPA inhibits the IKKa kinase activity,
whereas GlcN does not. Interestingly, both GlcN and NAPA inhibit IKKa nuclear re-localization.
Conclusions: Our results demonstrate that glucosamine and its peptidyl derivative can interfere with NF-B
signaling pathway by inhibiting IKKa activity in human chondrocytes. However, the mechanism of action of the
two molecules is not completely overlapping. While NAPA can both specifically inhibit the IKKa kinase activity and
IKKa nuclear re-localization, GlcN only acts on IKKa nuclear re-localization.
Introduction
Osteoarthritis (OA), the most common rheumatic dis-
ease, is a major cause of disability. It is strongly asso-
ciated with aging and its medical relevance is rising in
the Western population given the increasing proportion
of older people. This pathology is characterized by pro-
gressive destruction of the extracellular matrix (ECM),
causing pain and disability in patients. OA is a non-cur-
able disease and its pharmacological treatment is based
mainly on analgesic agents or non-steroidal anti-inflam-
matory drugs (NSAIDs). Structure-modifying agents are
also administered to OA patients, with the aim of pre-
venting or delaying cartilage degradation by pharmaco-
logical treatment [1]. Several chondroprotective agents,
such as glucosamine (GlcN), condroitin sulfate, diacer-
ein and curcumin, have been studied [2-6]. To date, stu-
dies performed in vivo and in vitro on GlcN and
condroitin sulfate have provided partially inconsistent
results [7-11]. Since these agents are widely available
and generally well tolerated and possess safer profiles
compared with NSAIDs, it is important to understand
their mechanism of action in detail.
We have previously studied GlcN and its N-acetyl
phenylalanine derivative (NAPA) in vivo,i na na n i m a l
model and in vitro, in primary chondrocytes and in an
immortalized cell line. In the in vivo study, we found
that both GlcN and NAPA were very effective in redu-
cing cartilage changes induced in rabbit knee by intra-
articular injection of vitamin A [12]. In the in vitro
study, GlcN and NAPA were able to counteract the
effects induced by inflammatory cytokines, tumor
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both in human primary chondrocytes and in immorta-
lized cell line lbvpa55 [13,14]. Interestingly, we found
that GlcN inhibits matrix metalloproteinase production
by inhibiting the phosphorylation of the mitogen-acti-
vated protein (MAP) kinases involved in the activation
of activator protein-1 (AP-1) transcription factor com-
plex [14]. NAPA showed the same behaviour (unpub-
lished data). Furthermore, we found that several genes
upregulated by TNFa are modulated by GlcN and
NAPA [13]. Since these genes are under the control of
nuclear factor-kappa-B (NF-B) transcription factor, we
decided to analyze their mechanism of action in the
context of the NF-B pathway.
NF-B is a family of transcription factors that play an
important role in the immune system and that can influ-
ence gene expression events with an impact on cell survi-
val, differentiation and proliferation [15,16]. The
mammalian NF-B family consists of five related tran-
scription factors: p50, p52, p65 (RelA), c-Rel and RelB.
The established model of NF-B action states that, in
unstimulated cells, inhibitor B proteins (IBs) sequester
the inactive transcription factor in the cytoplasm. Stimu-
latory events lead to IB protein phosphorylation, ubiqui-
tylation and subsequent degradation. The end result is
the release of the cytoplasmic NF-Bc o m p l e x ,w h i c h
moves into the nucleus, where it drives the expression of
its target genes [15-17]. The kinase responsible for IB
phosphorylation is the inhibitor Bk i n a s e( I K K )c o m -
plex. Two components of the IKK complex, IKKa and
IKKb, are involved in the release of the NF-B active
form. Proinflammatory stimuli activate IKKb,w h i c hi s
essential for IBa degradation. In contrast, IKKa only
rarely activates IBa [18] but has been reported to acti-
vate the NF-B pathway by working as a nucleosomal
kinase [19,20] that stimulates a distinct class of genes
[21]. Moreover, a differential role of IKKa and IKKb in
the physiology and progression of OA chondrocytes was
recently reported, suggesting that the OA phenotype is
more related to IKKa than to IKKb [22].
The aim of the present study is to investigate whether
GlcN and NAPA could affect the activation of IKKa
and IKKb in chondrocytes stimulated with the proin-
flammatory cytokine TNFa. We found that NAPA and,
albeit to a lesser extent, GlcN inhibit the expression of
genes under NF-B control. We analyzed the effect of
both molecules on IBa phosphorylation and on p65
nuclear translocation. We also evaluated whether NAPA
and GlcN could affect IKKa and IKKb activation and
IKKa nuclear translocation. To circumvent the limita-
tions of human primary chondrocytes such as poor
yield, low proliferation and inter-individual variability of
donor samples, we conducted the study on the immor-
talized cell line HTB-94 (SW1353; American Type
Culture Collection, Manassas, VA, USA). For confirma-




The HTB-94 human chondrosarcoma cell line
( S W 1 3 5 3 )w a sp u r c h a s e df r o mA m e r i c a nT y p eC u l t u r e
Collection and was grown in Dulbecco’sm o d i f i e d
Eagle’sm e d i u m( D M E M )( H y C l o n e ,L o g a n ,U T ,U S A )
supplemented with L-glutamine, penicillin/streptomycin
(HyClone), plus 10% fetal bovine serum (FBS). Experi-
ments were performed in DMEM containing 1% FBS.
Human primary chondrocytes were isolated as pre-
viously described [14] from cartilage obtained from
healthy donors. Full ethical consent was obtained from
all donors, and the experiments were performed in
accordance with Sapienza University of Roma ethics
committee guidelines. Cells were used at first passage in
DMEM containing 1% FBS.
Cell treatment
The HTB-94 cell line has been previously shown to be a
good model to study inflammatory pathways [23]. Cells
were seeded in plates at the required density. Cells were
left untreated (CTL) or treated with 10 ng/mL recombi-
nant TNF-a (PeproTech EC Ltd., London, UK) or pre-
treated for 2 hours with 5 and 10 mM GlcN (Sigma-
Aldrich, St. Louis, MO, USA) or with 2-(N-Acetyl)-L-
phenylalanylamido-2-deoxy-b-D-glucose (NAPA),
synthesized as previously reported [24]. After pre-incu-
bation, the cells were stimulated with 10 ng/mL TNF-a
for the required time. Cells were analyzed by immuno-
cytochemistry or harvested and processed for quantita-
tive real-time polymerase chain reaction (Q-RT-PCR),
for Western blot analysis and for immunoprecipitation.
RNA extraction and reverse transcription
Total RNA was extracted using TRIZOL reagent (Invi-
trogen Corporation, Carlsbad, CA, USA) in accordance
with the manufacturer’s instructions. Briefly, a confluent
60-mm plate of HTB-94 or human primary chondro-
cytes was washed with phosphate-buffered saline (PBS)
and homogenized in 1 mL of TRIZOL reagent. RNA
w a ss t o r e da t- 8 0 ° Cu n t i lu s e d .c D N Aw a ss y n t h e s i z e d
from 1 μg of total RNA, using reverse transcriptase
Improm II (Promega Corporation, Madison, WI, USA)
in accordance with the manufacturer’si n s t r u c t i o n s ,a n d
analyzed by Q-RT-PCR.
Real-time polymerase chain reaction
Q-RT-PCR analysis was performed using an ABI Prism
7300 (Applied Biosystems, Foster City, CA, USA). Amplifi-
cation was carried out with 50 ng of cDNA, in 96-well
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systems) in a volume of 25 μL. Each sample was analyzed
in triplicate. PCR conditions were 94°C for 10 minutes fol-
lowed by 40 cycles of 94°C for 15 seconds and 60°C for 1
minute. Primers were designed using Primer Express soft-
ware (Applied Biosystems) and were synthesized by
Primm (Milan, Italy). The following primers were used:
IL-6 forward, 5’-TGGCCTGAAAAAGATGGATGCT-3’;
IL-6 reverse, 5’-AACTCCAAAAGACCAGTGATGATTT-
3’ (NM_000600); IL-8 forward, 5’-AGATATTGCACGG-
GAGAATATACAAA-3’;I L - 8r e v e r s e ,5 ’-GCAAACC-
CATTCAATTCCTGAA-3’ (NM_000584); IBa forward,




(NM_000201.2); Mcp-1 forward 5’-CGCTCAGCCA-
GATGCAATC-3’; Mcp-1 reverse, 5’-GCACTGAGATC-
TTCCTATTGGTGAA-3’ (NM_02982); glyceraldehyde-




The results were analyzed using the Sequence Detec-
tion Systems software (Applied Biosystems), which auto-
matically recorded the threshold cycle (Ct). Untreated
cell sample (CTL) was used as calibrator. The fold
change for CTL was 1.0. Target gene Ct values were
normalized against GAPDH. Data were analyzed using
the 2
ΔΔCt method and expressed as fold change com-
pared with CTL.
Western blotting
Human primary chondrocytes, treated as described
above, were washed with PBS and lysated by nuclear
extract kit (Active Motif, Carlsbad, CA, USA) to sepa-
rate the cytosolic from the nuclear extract in accordance
with the manufacturer’s instructions. Extracts were
resolved on 10% SDS-PAGE. Gels were transferred to
Hybond C membranes (GE Healthcare Europe, Milan,
Italy) by electroblotting (Bio-Rad Laboratories, Inc., Her-
cules, CA, USA) and probed with specific antibodies in
accordance with the manufacturer’s instructions. Anti-
bodies against IKKa and b-actin were purchased from
Sigma-Aldrich, and antibodies against fibrillarin, p-IBa
and p65 were from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). Where indicated, the intensity
of bands was compared by densitometric analysis using
ImageJ 1.41 (National Institutes of Health, Bethesda,
MD, USA) and reported as fold change.
Immunoprecipitation of the IKK complex
To immunoprecipitate the activated IKK complex, HTB-
94 cells were treated with 10 ng/mL TNFa for 10
minutes, scraped and homogenized in lysis buffer pH
7.5 (50 mM TRIS-Cl, 100 mM NaCl, 1% NP40, 0.25%
Na-deossycolate, 1 mM EDTA). Whole-cell lysate (200
μg) was incubated with anti-IKKa antibody (Sigma-
Aldrich) at 4°C for 16 hours and next treated with pro-
tein A-Agarose beads (Santa Cruz Biotechnology, Inc.).
A f t e r2 - h o u ri n c u b a t i o n ,t h e beads were extensively
washed with lysis buffer and assayed in an in vitro
kinase assay as detailed below.
Kinase assay
To determine the effect of NAPA and GlcN on TNFa-
induced IKK complex activation, we performed an
immunocomplex kinase assay. Immunoprecipitated (IP)-
IKK complex, recombinant IKKa (Invitrogen Corpora-
tion) and IKKb (Invitrogen Corporation) were analyzed
by kinase assay in a mixture containing 50 mM Tris-Cl
pH 7.4, 100 mM NaCl, 10 μCi g-
32P-ATP (PerkinElmer
Italia - Life and Analytical Sciences, Monza [Milan],
Italy), 5 mM MgCl2,1m MD T Ta n d2μgo fs u b s t r a t e
glutatione S-transferase (GST) IBa (Santa Cruz Bio-
technology, Inc.) in the presence or absence of different
concentrations of GlcN or NAPA. Kinase assay was per-
formed at 30°C for 30 minutes, and the reaction was
stopped by boiling with SDS sample buffer (Sigma-
Aldrich) for 5 minutes. Finally, the proteins were
resolved on 10% SDS-PAGE and transferred to Hybond
C membranes (GE Healthcare Europe) by electroblotting
(Bio-Rad Laboratories, Inc.). Membrane was exposed to
x-ray film to visualize the radioactive bands. To deter-
mine the total amounts of IKKa/b in each IP sample,
the same membrane was probed with anti-IKKa
antibody.
Immunocytochemistry and confocal microscopy
IKKa nuclear re-localization was visualized by confocal
microscopy. HTB-94 cells were untreated (CTL) or trea-
ted with 10 ng/mL TNFa and with GlcN or NAPA plus
TNFa. After treatment, cells were fixed with 4% paraf-
ormaldehyde and permeabilized with 0.3% Triton X-100.
After washing with PBS, the cells were incubated over-
night at 4°C with monoclonal anti-IKKa (sc-7606; Santa
Cruz Biotechnology, Inc.) (diluted 1:50), washed with
PBS and incubated for 1 hour at room temperature with
Alexa Fluor 488 goat anti-mouse antibody (Invitrogen
Corporation) (diluted 1:300). Slides were washed, incu-
bated with DAPI (diamidino-2-phenylindole) (Invitrogen
Corporation) to visualize nuclei, mounted and analyzed
with a Leica 2500 confocal microscopy (Leica Microsys-
tems, Wetzlar, Germany).
Assessment of cell viability
To detect potential cytotoxic effects of NAPA, the survi-
val of the cells treated with this molecule was evaluated
Scotto d’Abusco et al. Arthritis Research & Therapy 2010, 12:R18
http://arthritis-research.com/content/12/1/R18
Page 3 of 11using MTT (3- [4,5-dimethylthiazol-2-yl]-2,5-di-phenyl-
tetrazolium bromide)-based colorimetric assay (Sigma-
Aldrich) in accordance with the manufacturer’si n s t r u c -
tions. Briefly, 1.5 × 10
4 cells per well were seeded in a
96-well plate in a volume of 150 μL. NAPA was added
at concentrations of 1, 2.5, 5 and 10 mM. Fifteen micro-
litres of MTT, a soluble tetrazolium salt solution, was
added to the well 24, 48 and 96 hours after treatment,
and the plate was incubated for an additional 4 hours.
Afterwards, the culture medium was removed and 150
μL of solvent solution was added to dissolve the MTT
formazan crystals. Spectrophotometric absorbance was
measured at a wavelength of 570 nm. The background
at 690 nm was subtracted.
Statistics
Each experiment was performed at least three times.
The statistical significance of the differences between
mean values was determined by a two-tailed t test; P
value of not more than 0.05 was considered significant.
When appropriate, results are expressed as the mean ±
standard error of the mean.
Results
GlcN and NAPA prevent the overexpression of
TNFa-stimulated genes
Previously, we found that both in immortalized cell line
and in rabbit primary chondrocytes, GlcN and NAPA
were able to counteract the TNFa upregulation of some
genes, such as TNFR-1 and TNFR-2, TRAF-6 and
IGFBP-6, whose transcription is under the control of
NF-B [12,13]. To explore whether GlcN and NAPA
affect the NF-B pathway in HTB-94 cells, we also ana-
lyzed the expression of other NF-B-regulated genes.
IL-6, IL-8, ICAM-1, Mcp-1 and IBa mRNA expression
levels were upregulated after 1-hour stimulation with
TNFa. Two-hour pre-treatment with 10 mM of both
molecules significantly reverted the stimulation of IL-6,
IL-8, ICAM-1 and Mcp-1, whereas the effect on IBa
was negligible. The effect of GlcN and NAPA at a con-
centration of 5 mM was not significant (Figure 1). The
same result was obtained in human primary chondro-
cytes (data not shown).
GlcN and NAPA slightly affect IBa phosphorylation and
p65 nuclear migration
To determine whether GlcN and NAPA affected IBa
phosphorylation, we analyzed the latter protein by Wes-
tern blot. IBa was significantly phosphorylated in the
cytosolic extract of cells stimulated with TNFa for 10
minutes. A 2-hour pre-treatment with GlcN and NAPA
did not significantly inhibit IBa phosphorylation
( F i g u r e2 a ) .S i n c eac o n c e n t r a t i o no f5m Mo fe i t h e r
molecules was ineffective in modulating gene expression,
the experiments were performed with only 10 mM of
both molecules. We investigated whether GlcN and
Figure 1 Effect of glucosamine (GlcN) and NAPA on mRNA expression level in HTB-94 cells. Cells were untreated (CTL), treated with
tumor necrosis factor-alpha (TNFa) or pre-treated with 5 and 10 mM GlcN (G5 and G10) or NAPA (N5 and N10) and then stimulated with TNFa
for 1 hour. The mRNA was extracted and analyzed by quantitative real-time polymerase chain reaction (Q-RT-PCR). The mRNA levels of IL-6, IL-8,
ICAM-1, Mcp-1 and IBa are shown in (a), (b), (c), (d) and (e), respectively. *P ≤ 0.05. Q-RT-PCR results are expressed as relative mRNA level.
Results represent the mean ± standard error of the mean of data obtained by three independent experiments. NAPA, 2-(N-Acetyl)-L-
phenylalanylamido-2-deoxy-b-D-glucose.
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the nucleus. Nuclear extract of cells treated for 10 min-
utes with TNFa showed that p65 was localized in the
nucleus, an effect only very moderately inhibited by
GlcN and NAPA, as expected given their minor effect
on IBa phosphorylation (Figure 2b). The same result
was obtained on human primary chondrocytes (data not
shown).
NAPA affects the kinase activity of IKK complex
IB phosphorylation is mediated by the IKK complex.
To determine whether GlcN and NAPA interfere with
the IKK kinase activity, we treated HTB-94 cells with
TNFa and the IKK complex was immunoprecipitated
using an anti-IKKa antibody from whole-cell extracts.
The IP-IKK complex was analyzed in an in vitro kinase
assay using a recombinant GST-IBa protein as sub-
strate both in the absence and in the presence of GlcN
and NAPA. In the first case, activated IP-IKK was able
to phosphorylate GST-IBa, demonstrating that TNFa
activates the IKK complex in our experimental model.
GlcN was not able to inhibit GST-IBa phosphorylation
(Figure 3a), whereas NAPA inhibited GST-IBa phos-
phorylation at a concentration of 0.5 mM (Figure 3b).
To distinguish between the effects of IKKa and IKKb,
we analyzed the inhibition of IKK kinase activity on
GST-IBa by GlcN and NAPA, using recombinant
IKKa and IKKb molecules. GlcN was not able to inhibit
either IKKa or IKKb at either concentration used (0.25
and 0.5 mM) (Figure 3c, e). On the contrary, NAPA
strongly inhibited the IKKa kinase activity on itself and
on GST-IBa at both concentrations (Figure 3d) but
did not affect the IKKb kinase activity on itself or on
GST-I Ba (Figure 3f). In these experiments, we were
able to use lower concentrations of GlcN and NAPA
(0.25 and 0.5 mM) than those used on intact cells (10
mM) because the molecules can directly interact with
the kinases without needing to cross the cell membrane.
GlcN and NAPA inhibit IKKa nuclear migration
IKKb activates the canonical NF-B pathway by phos-
phorylation of IBa,w h e r e a sI K K a is not required to
phosphorylate IBa, but it plays an important role by
localizing into the nucleus of activated cells and indu-
cing the transcription of NF-B-dependent genes. To
determine whether GlcN and NAPA could inhibit the
IKKa nuclear translocation, we analyzed its subcellular
localization by immunocytochemistry. Detection of
IKKa revealed that this protein is mainly cytoplasmic in
unstimulated cells, while it accumulates in the nucleus
Figure 2 Effect of glucosamine (GlcN) and NAPA on IBa phosphorylation level and on p65 nuclear translocation.H T B - 9 4c e l l sw e r e
untreated (CTL), treated with tumor necrosis factor-alpha (TNFa) or pre-treated with 5 and 10 mM GlcN (G5 and G10) or NAPA (N5 and N10)
and then stimulated with TNFa for 10 minutes. (a) Cytosolic extract probed with antibodies against phospho-IBa (p-IBa) and b-actin. (b)
Nuclear extract probed with antibodies anti-p65 and fibrillarin. Band intensities were quantified as reported in Materials and methods. Results are
expressed as fold changes with respect to control. The data are representative of three independent experiments. A.U., arbitrary units; NAPA, 2-
(N-Acetyl)-L-phenylalanylamido-2-deoxy-b-D-glucose.
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GlcN and NAPA and subsequently stimulated with
TNFa showed a prevalent cytoplasmic IKKa localization
(Figure 4). This result was confirmed in human primary
chondrocytes by Western blot analysis in which both
GlcN and NAPA were able to inhibit the re-localization
of IKKa into nuclei (Figure 5a, b).
NAPA inhibits nuclear IKKa kinase activity on histone H3
Several authors have shown that IKKa, after translocat-
ing into the nucleus, phosphorylates histone H3, thereby
permitting the transcription of several genes under NF-
B control [19,20,25]. We investigated whether NAPA
could inhibit the IKKa-dependent phosphorylation of
histone H3 and indeed found that this is the case (Fig-
ure 6a). Interestingly, GlcN does not inhibit histone H3
phosphorylation (Figure 6b).
NAPA does not interfere with chondrocyte viability
To assess the potential cytotoxic effect of NAPA on
human chondrocytes, we performed an MTT cell viabi-
lity assay. The results show that NAPA does not affect
cellular viability at any investigated concentrations or
times (Figure 7).
Figure 3 Effect of glucosamine (GlcN) and NAPA on inhibitor B kinase (IKK) kinase activity. HTB-94 cells were stimulated for 10 minutes
with tumor necrosis factor-alpha (TNFa), IKK complex was immunoprecipitated from whole-cell extract with an anti-IKKa antibody and an in
vitro kinase assay was performed. (a) Kinase assay on recombinant glutatione S-transferase (GST)-IBa in the absence (-) or presence of 0.25 and
0.5 mM GlcN. (b) Kinase assay on recombinant GST-IBa in the absence (-) or presence of 0.25 and 0.5 mM NAPA. Normalization was obtained
by Western blot analysis using anti-IKKa antibody. (c) IKKa kinase activity on itself, using IKKa recombinant protein, in the absence (-) or
presence of 0.25 and 0.5 mM GlcN. (d) IKKa kinase activity on GST-IB substrate in the absence (-) or presence of 0.25 and 0.5 mM NAPA. (e)
IKKb kinase activity on itself, using IKKb recombinant protein, in the absence (-) or presence of 0.25 and 0.5 mM GlcN. (f) IKKb kinase activity on
GST-IB substrate in the absence (-) or presence of 0.25 and 0.5 mM NAPA. Grey bars indicate auto-phosphorylation of IKKa or IKKb as indicated,
and dark grey bars show GST-IBa phosphorylation. *P ≤ 0.05. Results are expressed as fold change with respect to control. NAPA, 2-(N-Acetyl)-
L-phenylalanylamido-2-deoxy-b-D-glucose.
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immunofluorescence. HTB-94 cells were untreated (CTL), stimulated with tumor necrosis factor-alpha (TNFa) or pre-treated for 2 hours with 10
mM GlcN (G10) or NAPA (N10) and then stimulated with TNFa for 1 hour. Cells were then processed for indirect immunofluorescence and
stained with anti-IKKa antibodies. Nuclei were stained with diamidino-2-phenylindole (DAPI). NAPA, 2-(N-Acetyl)-L-phenylalanylamido-2-deoxy-b-
D-glucose.
Figure 5 Effect of glucosamine (GlcN) and NAPA on inhibitor B kinase alpha (IKKa) nuclear translocation in human primary
chondrocytes. The analysis was performed by Western blot. Cells were untreated (CTL), treated with tumor necrosis factor-alpha (TNFa) or pre-
treated with 10 mM GlcN (G10) or NAPA (N10) and then stimulated with TNFa for 1 hour. (a) Cytosolic extract probed with antibodies against
IKKa and b-actin. (b) Nuclear extract probed with antibodies against IKKa and fibrillarin. *P ≤ 0.05. Results are expressed as fold change with
respect to control. A.U., arbitrary units; NAPA, 2-(N-Acetyl)-L-phenylalanylamido-2-deoxy-b-D-glucose.
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T h ea i mo ft h ep r e s e n ts t u d yw a st oi n v e s t i g a t et h e
mechanism by which GlcN and its derivative NAPA
affect the activation of the NF-B transcription factor.
NF-B is an important regulator of the immune
response but is also involved in a wide variety of stress
responses and transcriptionally activates many genes
with an important role in proliferation and matrix
degradation.
Previously, we showed that the transcription of several
genes under NF-B control and stimulated by TNFa
was modulated by both molecules [13]. Here, we show
that other genes under NF-Bc o n t r o l ,s u c ha sIL-6, IL-
8, ICAM-1 and Mcp-1, are modulated as well in the
HTB-94 chondrosarcoma cell line stimulated with
TNFa. Proinflammatory cytokines can stimulate the
NF-B pathway by activating IKK complex, which is
made up of IKKa,I K K b and IKKg/NEMO. The two
Figure 6 Effect of glucosamine (GlcN) and NAPA on inhibitor B kinase alpha (IKKa) kinase activity using recombinant histone H3 as
substrate. (a) IKKa kinase assay on recombinant histone H3 in the absence (-) or presence of 0.25 and 0.5 mM GlcN. (b) IKKa kinase assay on
recombinant histone H3 in the absence (-) or presence of 0.25 and 0.5 mM NAPA. *P ≤ 0.05. Results are expressed as fold change with respect
to control. NAPA, 2-(N-Acetyl)-L-phenylalanylamido-2-deoxy-b-D-glucose.
Figure 7 Effect of NAPA on cell viability. Cellular viability was assessed by MTT (3- [4,5-dimethylthiazol-2-yl]-2,5-di-phenyltetrazolium bromide)
method after 24, 48 and 96 hours, with different concentrations of NAPA as indicated. NAPA, 2-(N-Acetyl)-L-phenylalanylamido-2-deoxy-b-D-
glucose; OD, optical density.
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whereas NEMO is a regulator subunit [26].
In the canonical NF-B pathway, IKKb is sufficient for
phosphorylation of IBa, leading to its degradation and
thereby allowing the translocation of p50/p65 in the
nucleus [27]. On the other hand, after stimulation,
IKKa itself migrates into the nucleus, where it stimu-
lates gene transcription [19,28-30]. We tested the ability
of GlcN and NAPA to inhibit IBa phosphorylation and
p65 nuclear translocation, finding that both molecules
are weakly effective. Our results suggested that NF-B-
dependent gene modulation should be attributed to
IKKa rather than to IKKb.I na nin vitro kinase assay,
we analyzed the IP-IKK complex and found that GST-
IBa phosphorylation was mediated by the activated
complex in the absence of NAPA or GlcN. This phos-
phorylation was inhibited by NAPA, while no effect of
GlcN was detected. To dissect the roles of IKKa and
IKKb,w er e p e a t e dt h ein vitro kinase assay using the
individual recombinant kinases. Interestingly, we found
that NAPA inhibited IKKa-mediated auto-phosphoryla-
tion and phosphorylation of GST-IBa but had no
effect on IKKb.W h e nI K K a migrates into the nucleus,
it phosphorylates some substrates, derepressing the NF-
B target genes [31,32]. Among IKKa-phosphorylated
substrates is the histone H3, which is subsequently
acetylated [25]. This is a crucial step in modulating
chromatin accessibility at NF-B responsive promoter
[19,20]. We found that NAPA can also inhibit H3 phos-
phorylation by IKKa, suggesting that this molecule is a
specific inhibitor of IKKa kinase activity. GlcN was not
able to inhibit either IKKa or IKKb kinase activity.
We tested whether TNFa stimulates the migration of
IKKa into the nucleus in chondrocytes as is the case in
other cell types [19,20,25,26,33] and whether the effect
could be inhibited by GlcN and NAPA. Indeed, TNFa
stimulates a massive re-localization of IKKa into the
nucleus in HTB-94 cell line and in human primary chon-
drocytes and both GlcN and NAPA are able to inhibit
this migration. We could not detect an appreciable
decrease of cytosolic IKKa in TNFa-stimulated cells,
because of the high concentration of IKKa in this com-
partment. This result is in accordance with what was
observed in other cell types [19,20,25,28,33]. The effec-
tiveness of GlcN and NAPA in inhibiting IKKa nuclear
migration explains the ability of these molecules to mod-
ulate the expression level of genes under NF-B control.
Our data, in agreement with what was reported in
[25], show that the absence of IKKa nuclear transloca-
tion and the inhibition of IKKa kinase activity modulate
the transcription of genes under NF-B control, regard-
less of the presence of p65, which is in the nucleus of
GlcN- and NAPA-treated cells. Recently, a role for
IKKa in accelerating nuclear clearance of p65 in
macrophages was reported [34]. This could explain the
nuclear accumulation of p65 that we observe in chon-
drocytes treated with both molecules: by inhibiting
IKKa nuclear translocation, they might impair nuclear
clearance of p65. Moreover, IKKa enhances promoter
clearance in the nucleus [31,32] and recruits and med-
iates the phosphorylation of proteins [35], allowing
binding of p65 to B sequences. Consequently, the sup-
pression of IKKa nuclear re-localization is expected to
inhibit p65 binding.
In the IKKa kinase domain, a nuclear localization




238, is present [33]. It has been shown that
inactivation of NLS by site-direct mutagenesis prevents
nuclear translocation but does not interfere with its
kinase activity. To inhibit IKKa nuclear translocation,
GlcN and NAPA should interfere with the NLS presum-
ably by interacting with the lysine residues. This is con-
sistent with their atomic structure since they are both
stable pyranose hemiacetals in equilibrium with the
open form in solution. The free aldehyde groups could
react with the NH2 group of the lysine side chains.
NAPA affects not only the nuclear translocation but
also the kinase activity of IKKa. This is of relevance
since inhibitors of enzymatic reactions are better suited
for further optimization to increase their activity or
pharmacokinetics properties.
It has been recently found that phenylethyl isothiocya-
nate shows anti-inflammatory properties acting via an
attenuation of the NF-B pathway in cancer cells
[36,37]. Like NAPA, this molecule has an aromatic ring.
This feature is shared by other molecules found to inhi-
bit NF-B activity, such as aspirine and salicylate [38],
aminosalicylic acid [39] and curcumin (diferuloyl-
methane) [5,40]. Consistently, the structural difference
between GlcN and its derivative is indeed the presence
of an aromatic phenylalanine residue.
Cell activation by TNFa increases the transcription of
the IBa gene, which is under the control of the cano-
nical NF-B pathway activated by IKKb [19,20,41]. GlcN
and NAPA were not able to revert this increase, and
this is consistent with the finding that both molecules
inhibit IKKa but not IKKb.
IKKa ablation was recently reported to show a
broader range of effects on OA chondrocytes, such as
enhanced ECM formation, due to the accumulation of
collagen II fibers [22] and an increased chondrocyte
proliferative capacity, a size reduction effect in undiffer-
entiated chondrocytes and an enhanced survival rate of
differentiated cells. It has been suggested that loss or
inhibition of IKKa could ameliorate the degenerative
aspects of OA chondrocytes, excessive ECM remodeling
and increased cell death. Furthermore, since IKKa abla-
tion increases the replicativep o t e n t i a la n ds u r v i v a lo f
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Page 9 of 11OA chondrocytes, our results could be useful in the
route of providing additional ways to attenuate OA pro-
gression. NAPA shows a specific effect on IKKa kinase
activity and does not affect IKKb kinase activity, and
this makes it an interesting candidate for the treatment
of the OA pathology.
Conclusions
We have previously shown that GlcN and NAPA were
both effective in restoring normal cartilage morphology
in injured rabbit joints and that GlcN can inhibit AP-1
activation by inhibiting MAP kinase phosphorylation.
Here, we show that GlcN and NAPA can also inhibit
NF-B activation and, specifically, that NAPA can inhi-
bit IKKa kinase activity. Further studies are required to
better understand the mechanism of action of the mole-
cule and which other effects, besides mRNA transcrip-
tion modulation, can be induced in cells. It has been
s u g g e s t e dt h a tI K K a inhibition could be a good strategy
for OA treatment. Our results suggest that the NAPA
peptidyl-GlcN derivative should be tested in association
to glucosamine in the pharmacological treatment of OA.
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